Category: Include on Menu
-

Summit Therapeutics Shares Plunge After Lung Cancer Drug Data Disappoints
Summit Therapeutics (NASDAQ:SMMT) saw its stock drop 23% in premarket trading after the company released updated longer-term follow-up data from its global trial of the investigational lung cancer therapy, ivonescimab. The new data failed to replicate the promising results previously observed in Chinese studies, raising concerns among investors and analysts. Findings indicated potential overall survival…
-

Premier Shares Jump Amid Rumors of Patient Square Capital Acquisition Talks
Shares of Premier Inc (NASDAQ:PINC) climbed more than 8% in premarket trading on Monday after a Bloomberg News report suggested that Patient Square Capital is exploring a potential acquisition of the healthcare services company. The report, released Friday, cited sources familiar with the discussions, noting that negotiations are still in the early stages. There is…
-

Rapport Therapeutics Surges After Promising Mid-Stage Seizure Drug Trial
Shares of Rapport Therapeutics (NASDAQ:RAPP) skyrocketed 160% after the biotech firm released encouraging topline data from a Phase 2a study of its experimental therapy RAP-219 in patients with focal onset seizures. The trial achieved its primary endpoint with strong statistical significance, showing a 71% median reduction in long seizure episodes, a recognized electrographic marker of…
-

Planet Labs Jumps After Delivering Record Revenue and Upbeat Outlook
Planet Labs PBC (NYSE:PL) saw its shares climb more than 9% in pre-market trading on Monday after unveiling second-quarter results that beat Wall Street forecasts and came with a brighter outlook for the year. For the quarter ending July 31, 2025, the Earth imaging company generated $73.4 million in revenue, up 20% from the same…
-

Eli Lilly’s Jaypirca hits key milestone in leukemia study
Eli Lilly (NYSE:LLY) reported that its phase 3 study of Jaypirca achieved the main goal in treating patients with chronic lymphocytic leukemia (CLL). According to the company, results from the BRUIN CLL-313 and BRUIN CLL-314 trials will serve as the foundation for applications to expand the drug’s approved use into earlier stages of treatment. The…
-

Tesla’s U.S. EV Market Share Slips to Lowest Level Since 2017
Tesla’s (NASDAQ:TSLA) dominance in the American electric vehicle market continued to weaken in August, with its share dropping to levels not seen in nearly eight years, according to a Reuters report citing Cox Automotive data. Figures showed that Tesla represented just 38% of U.S. EV sales last month, falling under the 40% mark for the…
-

UBS Warns iPhone Price Hikes Could Hurt Demand
Apple’s upcoming iPhone launch may face headwinds if prices are increased, UBS analysts cautioned in a note. Apple (NASDAQ:AAPL) is scheduled to host its “Awe Dropping” event on Tuesday, September 9, where the company is expected to reveal its latest devices, including the iPhone 17 lineup. UBS highlighted that any implicit or explicit price hike…
-

Eightco Shares Skyrocket Following $250M Private Placement to Back Worldcoin Strategy
Eightco Holdings Inc. (NASDAQ:OCTO) saw its stock surge 350% after revealing a $250 million private placement alongside a $20 million strategic investment from BitMine Immersion Technologies (NYSE:BMNR), aimed at executing what the company calls the “world’s first Worldcoin treasury strategy.” The capital raised will be primarily used to acquire Worldcoin (COIN:WLDUSD) as Eightco’s main treasury…
-

Chrysler Minivans Face Federal Probe Over Steering Concerns
The U.S. National Highway Traffic Safety Administration (NHTSA) announced on Monday that it has launched an investigation into roughly 287,000 Chrysler minivans produced by Stellantis (NYSE:STLA), citing potential issues with their electric power steering systems. The review focuses on Chrysler Pacifica models from the 2017 and 2018 model years. According to NHTSA, the agency has…
-

Five Key Market Themes for the Week Ahead
This week, global markets are set to focus on a mix of economic data, corporate earnings, and political developments. The U.S. inflation report will be a key driver, as investors anticipate how the Federal Reserve might respond with interest rate adjustments later this month. Corporate watchers are eyeing Oracle (NYSE:ORCL) for insights on the AI…